Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Novartis Ending RNAi Research Partnership, Alnylam Trims Workforce

This article was originally published in The Pink Sheet Daily

Executive Summary

In ending the five-year collaboration, Novartis said it will work to develop RNAi therapeutics against 31 targets, which could bring Alnylam significant milestones down the road.
Advertisement

Related Content

Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe
From Friends To Foes: Tekmira Slaps Partner Alnylam With Lawsuit
From Friends To Foes: Tekmira Slaps Partner Alnylam With Lawsuit
Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

Topics

Advertisement
UsernamePublicRestriction

Register

PS071233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel